CagriSema

CagriSema co-formulates semaglutide 2.4 mg, a GLP-1 receptor agonist, with cagrilintide 2.4 mg, a long-acting synthetic amylin analogue. The two components engage complementary neuronal circuits governing appetite, gastric emptying, and glucose homeostasis.

Semaglutide activates GLP-1 receptors in the gut, brainstem, and hypothalamus, stimulating glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing food intake via central satiety pathways.

Cagrilintide is a 37-amino-acid amylin analogue bearing a C18 fatty diacid moiety that confers reversible albumin binding and extends plasma half-life to approximately 159-195 hours, enabling once-weekly dosing. It is a dual amylin receptor (AMY1R, AMY2R, AMY3R) and calcitonin receptor co-agonist; weight-reducing effects are primarily mediated through AMY1R and AMY3R in the hindbrain area postrema, a circumventricular organ outside the blood-brain barrier with direct access to the systemic circulation. Activation suppresses appetite, slows gastric emptying, and inhibits glucagon via pathways distinct from GLP-1 signaling. Structural studies (Nature Communications, 2025) show cagrilintide adopts an amylin-like binding mode but induces distinct conformational dynamics at these receptors compared with native amylin, partly through an intramolecular ionic lock and a C-terminal proline substitution.

Combining both agents produces synergistic reductions in food intake and body weight exceeding either monotherapy.

Clinical development spans phase 1b through phase 3 trials conducted by Novo Nordisk.

A 20-week phase 1b randomized trial (The Lancet, 2021) in individuals with overweight or obesity found cagrilintide 4.5 mg added to semaglutide 2.4 mg once weekly produced approximately 17.1% mean weight loss versus approximately 10% for semaglutide alone, establishing proof of concept for the combination.

A 32-week phase 2 randomized trial (The Lancet, 2023; n=92 adults with type 2 diabetes; PMID 37364590) found CagriSema reduced body weight by 15.6% versus 5.1% with semaglutide and 8.1% with cagrilintide alone. HbA1c fell 2.2 percentage points with the combination versus 1.8 with semaglutide.

REDEFINE 1 (NCT05567796), a 68-week phase 3 RCT in 3,417 adults without type 2 diabetes (NEJM, August 2025; PMID 40544433), found mean body weight reduction of 20.4% with CagriSema versus 3.0% with placebo (difference -17.3 percentage points; p<0.001). An on-treatment analysis estimated 22.7% weight loss. Sixty percent of CagriSema participants achieved at least 20% weight loss; 23% achieved at least 30%.

REDEFINE 2 (68 weeks; n=1,206 adults with type 2 diabetes; NEJM, 2025) found 13.7% mean weight reduction versus 3.4% placebo; 73.5% of CagriSema participants reached HbA1c of 6.5% or below versus 15.9% with placebo.

REIMAGINE 3 (The Lancet, 2026; PMID 42251856), a phase 3 trial adding CagriSema to basal insulin in adults with type 2 diabetes, demonstrated HbA1c reduction from approximately 8.8% to 6.5% and up to 12% weight loss without severe hypoglycemia. An FDA new drug application (NDA) was submitted in December 2025; FDA review was ongoing as of mid-2026. REDEFINE 4 (n=809; 84 weeks) showed substantial weight loss but did not meet the prespecified noninferiority margin versus tirzepatide 15 mg. REDEFINE 3, a cardiovascular outcomes trial enrolling approximately 7,000 patients with established cardiovascular disease, is ongoing with results expected approximately 2027-2028.

Typical dosage: Clinical trials (weekly).

In the phase 3 REDEFINE and REIMAGINE trials, CagriSema was administered as once-weekly subcutaneous injections with both components escalated in parallel on a five-step titration schedule to minimize gastrointestinal intolerability:

• Weeks 1-4: 0.25 mg cagrilintide / 0.25 mg semaglutide once weekly • Weeks 5-8: 0.5 mg / 0.5 mg once weekly • Weeks 9-12: 1.0 mg / 1.0 mg once weekly • Weeks 13-16: 1.7 mg / 1.7 mg once weekly • Week 17 onward: 2.4 mg / 2.4 mg once weekly (target maintenance dose)

A lower maintenance target of 1.0 mg/1.0 mg was evaluated in REIMAGINE 3 as an add-on to basal insulin and also demonstrated significant glycemic and weight benefits relative to placebo.

CagriSema had not received FDA approval as of mid-2026; no commercially approved prescribing label or final labeled dosing schedule was available at the time of writing. All dosing figures above are derived from published registrational trial protocols and may not reflect any final approved labeling. The drug exists in some markets as a compounded or research-use preparation; these formulations are not FDA-approved and are outside the scope of the published efficacy and safety data summarized here.

This information is provided for educational and reference purposes only and does not constitute medical advice. Dosing decisions must be made by a qualified healthcare provider in an appropriate clinical setting.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

CagriSema is itself a dual-agent combination. In published clinical trials, it was studied as an add-on to existing background therapy: metformin with or without an SGLT2 inhibitor in the phase 2 type 2 diabetes trial (The Lancet, 2023), and once-daily basal insulin in REIMAGINE 3 (The Lancet, 2026). In the latter setting, the addition of CagriSema to basal insulin produced significant glycemic and weight benefits without increasing the incidence of severe hypoglycemia, supporting its potential utility as an intensification strategy in insulin-treated type 2 diabetes.

No published phase 3 controlled data support combining CagriSema with additional obesity pharmacotherapies. REDEFINE 4 compared CagriSema against tirzepatide in a head-to-head design rather than testing co-administration. Community-level and compounding contexts include reports of cagrilintide being used alongside other GLP-1 or GIP/GLP-1 receptor agonists, but these practices have no controlled clinical trial evidence and carry unknown safety implications; they should be regarded as anecdotal only.

CagriSema is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Under study

In REDEFINE 1, gastrointestinal adverse events affected 79.6% of CagriSema participants versus 39.9% on placebo. The most common were nausea (55.0% vs 12.6%), constipation (30.7% vs 11.6%), and vomiting (26.1% vs 4.1%). These were predominantly mild to moderate in severity and generally resolved over time with continued use. Treatment discontinuation due to adverse events occurred in 5.9% of CagriSema participants in REDEFINE 1 and 8.4% in REDEFINE 2, versus 3.0-3.5% for placebo in each.

Based on the approved semaglutide component label (Wegovy) and class data, the following safety considerations apply:

• Thyroid C-cell tumors: rodent carcinogenicity studies showed proliferative C-cell changes; relevance to humans has not been established, but the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). • Acute pancreatitis: cases including fatal hemorrhagic or necrotizing pancreatitis have been reported with GLP-1 receptor agonists; patients should be monitored for persistent or severe abdominal pain. • Gallbladder disease: increased incidence of cholelithiasis and cholecystitis is associated with this drug class. • Hypoglycemia: low risk as monotherapy; higher risk when co-administered with insulin or sulfonylureas. REIMAGINE 3 reported no severe hypoglycemia when CagriSema was added to basal insulin.

Mild increases in resting heart rate and injection-site reactions are associated with GLP-1 class agents. Long-term cardiovascular safety is under evaluation in the ongoing REDEFINE 3 cardiovascular outcomes trial; no outcomes data from that trial were available as of mid-2026.